UK approves Oxford-AstraZeneca Covid-19 vaccine

UK approves Oxford-AstraZeneca Covid-19 vaccine

The pandemic has already killed 1.7 million people around the world

Representative image. Credit: Reuters

Britain on Wednesday became the first country in the world to approve a coronavirus vaccine developed by Oxford University and AstraZeneca as it battles a major winter surge driven by a new, highly contagious variant of the virus.

"The government has today accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise Oxford University/AstraZeneca’s Covid-19 vaccine for use," the health ministry said.

Coronavirus vaccine news live updates on DH

The UK's vaccine approval is crucial for India as Pune-based Serum Institute of India was yet to receive an approval from the Central Drug Standards Control Organisation due to the absence of such an approval from the UK drug regulator to the original vaccine created by a partnership between Oxford University and AstraZeneca.

Since the SII vaccine is the same as the Oxford-AstraZeneca one, Indian regulators wanted to look at the vaccine’s efficacy data from the clinical evaluations carried out abroad before permitting its emergency use in India.

Also read: Covishield vaccine ready for rollout in January: Serum Institute of India CEO Adar Poonawala

The pandemic has already killed 1.7 million people around the world, sown chaos through the global economy and upended normal life for billions since it began in Wuhan, China, a year ago.

Britain and South Africa, in particular, are grappling with new variants of the coronavirus, which the government and scientists say are more contagious; many countries have responded by banning passenger flights and blocking trade.

AstraZeneca and other developers have said they are studying the impact of the new variant but expect that their shots will be effective against it. The regulatory endorsement is a welcome boost for AstraZeneca and the Oxford team, which have been accused of a lack of clarity about the results from late-stage trials. 

(With agency inputs)